Article
CARRA (Childhood Arthritis and Rheumatology Research Alliance) has compared 3 different treatment strategies for polyarticular JIA to identify the optimal time to biologic regimen.
All News
Article
Patients with dermatomyositis who were positive for a myositis-specific antibody had a much higher incidence of and mortality associated with Pneumocystis jirovecii infection than patients with other antibody-negative idiopathic inflammatory myopathies, Chinese researchers found.
Article
Mease and colleagues have catalogued the current practices assessed in the CORRONA registry, noting that increased DMARD switching and decreased time on a given therapy by US physicians.
Article
Following is a statement from ACR President David Karp, MD, PhD, on JAK inhibitors and FDA drug safety communication.
Article
This week: high science that affect future treatments; breakthrough infections in our patients, and what's up with that; and soon your radiologist is going to be replaced by AI. This and more in our review of the news and journal articles from the past week.
Dr. John Cush
Tweet
Study of 265 students w/ a positive COVID-19 test looked at 378 close contacts. Infx rates w both persons masked -7.7%, but when unmasked-32.4% (aORs = 4.9;)
https://t.co/fYdH33JbWR
Dr. John Cush
Tweet
Cytokine Storm Management available for download.
https://t.co/dTAzMVa6SB https://t.co/i6yo351QRN
Dr. John Cush
Tweet
Have an interest in following healthcare trends and updates on Twitter? Dr. Rachel Tate ( @uptoTate ) shared the top three healthcare hashtags to follow. #RheumNow
https://t.co/pnRFNQA5BW https://t.co/5a3CzRtzwR
Dr. John Cush
Tweet
Mease and colleagues have catalogued the current practices assessed in the CORRONA registry, noting that increased DMARD switching and decreased time on a given therapy by US physicians.
https://t.co/cIWZw6KsuI https://t.co/SWcedXN2jm
Dr. John Cush
Tweet
ACR Comments on JAK Inhibitors and FDA Announcement
https://t.co/zDYInRQjTl https://t.co/xu9A8I7Frs
Dr. John Cush
Tweet
Baricitinib & Tofacitinib are effective in COVID-19 pts. These drugs are expensive; baricitinib is $44/tablet, but much lower for generics worldwide. 14 day course of TOFA would be >$1,400 in the US (but $600 in France, $25 in India) https://t.co/r2cn1H2z8i
Dr. John Cush
Tweet
NICE (UK) has recommended tofacitinib as an option for treating active polyarticular juvenile arthritis and juvenile psoriatic arthritis in people 2 years and older. https://t.co/9iLqzo36aD
Dr. John Cush
Tweet
Surveys of 125 clinic patients suggests an improved pt experience by Standardizing appt phone call script, updating appointment package, include a clinic visit prep checklist, to improve pt preparedness and reduce clinic cycle time. https://t.co/5sfBFpag8V
Dr. John Cush
Tweet
ICYMI:
Causes of DYSGEUSIA (metallic taste):
- Antibiotics (clarithromycin, metronidazole tetracycline), Allopurinol, captopril,
Lithium, Methazolamide, Metformin, Lunesta and more... heres a video discussion on this. https://t.co/FphprLh1Sf https://t.co/1wkjQxA9UZ https://t.co/kAFaKGiHiG
Dr. John Cush
Tweet
Cytokine Storm Overview Available for Download!
https://t.co/XRlx3OJDeR https://t.co/9mGnopNBTs
Dr. John Cush
Tweet
MMWR reports that during the COVID Delta variant era, Vaccination against COVID-19:
- Reduces risk of COVID-19 infection 5X
- Reduces risk of COVID-19 Hospitalization >10X
- Reduces risk of COVID-19 DEATH 10X
https://t.co/rMRY84xX5F
Dr. John Cush
Tweet
Probenecid, an OAT3 inhibitor, has inhibitory effects on RNA viruses (influenza, RSV) & decreases ACE2 expression. May have utility in COVID-19 as it was shown to inhibit SARS-CoV-2 replication in animal models https://t.co/MClSjpqpSa
Dr. John Cush
Tweet
ICYMI:
https://t.co/wM1iRxtHvk
The interleukin-6 inhibitor, tocilizumab (TCZ), was studied in a cohort of difficult systemic sclerosis (SSc) and was shown to be effective in refractory joint and skin disease with good long-term retention rates and disease stabilization. https://t.co/A8dfCksp3b
Dr. John Cush
Tweet
A retrospective study of systemic sclerosis patients shows that acute hospitalization and mortality were not uncommon and were often linked to SSc-related lung disease.
#RheumNow
https://t.co/s5wSlndTrt https://t.co/KHz9LYZVAK
Dr. John Cush
Tweet
J Hopkins study of 524 myositis-specific Ab positive pts shows that while 91% met 2017 EULAR/ACR criteria for Dx of myositis, 20% of HMGCR+ & 50% anti-PL7 did not classify as myositis; ~10% anti-SRP & HMGCR were dx as inclusion body myositis https://t.co/jcIn6SzbGG
